Advertisement

Diagnosis, Staging, and Follow-up

  • Dirk Schadendorf
  • Corinna Kochs
  • Elisabeth Livingstone
Chapter

Abstract

After carefully taking the patient’s medical history, their individual risk factors for melanoma should be assessed and evaluated. Patients should be asked if they have noticed the development of new lesions or changes in pre-existing ones

Keywords

Sentinel Lymph Node Sentinel Lymph Node Biopsy Primary Melanoma Gamma Probe Tumor Thickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292:2771-2776.Google Scholar
  2. 2.
    Malvehy J, Puig S, Argenziano G, Marghoob AA, Soyer HP; International Dermoscopy Society Board. Dermoscopy report: proposal for standardization: results of a consensus meeting of the International Dermoscopy Society. J Am Acad Dermatol. 2007;57:84-95.Google Scholar
  3. 3.
    Grob JJ, Bonerandi JJ. The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134:103-104.Google Scholar
  4. 4.
    Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3:159-165.Google Scholar
  5. 5.
    Bafounta M-L, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol. 2001;137:1343-1350.Google Scholar
  6. 6.
    Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159:669-676.Google Scholar
  7. 7.
    Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Evidence-Based Best Practice Guidelines. Wellington, New Zealand: Cancer Council Australia and Australian Cancer Network and the Sydney and New Zealand Guidelines Group; 2008.Google Scholar
  8. 8.
    Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust. 1997;167:191-194.Google Scholar
  9. 9.
    Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol. 2004;150:706-714.Google Scholar
  10. 10.
    McIntosh LM, Summers R, Jackson M, et al. Towards non-invasive screening of skin lesions by near-infrared spectroscopy. J Invest Dermatol. 2001;116:175-181.Google Scholar
  11. 11.
    Langley RGB, Walsh N, Sutherland AE, et al. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study. Dermatology. 2007;215:365-372.Google Scholar
  12. 12.
    Dimitrow E, Ziemer M, Koehler MJ, et al. Sensitivity and specificity of multiphoton laser tomography for in vivo and ex vivo diagnosis of malignant melanoma. J Invest Dermatol. 2009;129:1752-1758.Google Scholar
  13. 13.
    Gambichler T, Orlikov A, Vasa R, et al. In vivo optical coherence tomography of basal cell carcinoma. J Dermatol Sci. 2007;45:167-173.Google Scholar
  14. 14.
    Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 2010;28:316-318.Google Scholar
  15. 15.
    Tran KT, Wright NA, Cockerell CJ. Biopsy of the pigmented lesion—when and how. J Am Acad Dermatol. 2008;59:852-871.Google Scholar
  16. 16.
    Witheiler DD, Cockerell CJ. Sensitivity of diagnosis of malignant melanoma: a clinicopathologic study with a critical assessment of biopsy techniques. Exp Dermatol. 1992;1:170-175.Google Scholar
  17. 17.
    Tadiparthi S, Panchani S, Iqbal A. Biopsy for malignant melanoma–are we following the guidelines? Ann R Coll Surg Engl. 2008;90:322-325.Google Scholar
  18. 18.
    Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.Google Scholar
  19. 19.
    Malignes melanom: diagnostik, therapie und nachsorge. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). www.awmf.org/leitlinien/ detail/ll/032-024OL.html. Accessed June 20, 2013.
  20. 20.
    Garbe C, Eigentler TK, Bauer J, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. J Dtsch Dermatol Ges. 2011;9:690-699.Google Scholar
  21. 21.
    Piris A, Mihm MC Jr, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38:394-400.Google Scholar
  22. 22.
    World Health Organization classification of tumours. International Agency for Research in Cancer. www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/BB6.pdf. Accessed April 17, 2013.
  23. 23.
    Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444.Google Scholar
  24. 24.
    Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol. 2009;35:313-319.Google Scholar
  25. 25.
    Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30:2912-2918.Google Scholar
  26. 26.
    Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16:2018-2027.Google Scholar
  27. 27.
    Kunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20:330-337.Google Scholar
  28. 28.
    Kretschmer L, Starz H, Thoms K-M, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129:1435-1442.Google Scholar
  29. 29.
    Socrier Y, Lauwers-Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol. 2010;162:830-834.Google Scholar
  30. 30.
    Morton DL, Cochran AJ, Thompson JF, et al; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302-313.Google Scholar
  31. 31.
    Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713-1742.Google Scholar
  32. 32.
    Alazraki N, Glass EC, Castronovo F, Valdes Olmos RA, Podoloff D. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med. 2002;43:1414-1418.Google Scholar
  33. 33.
    Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011;364:1738-1745.Google Scholar
  34. 34.
    Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44:1413-1420.Google Scholar
  35. 35.
    Stoffels I, Scherag A, Klode J. SPECT/CT for sentinel lymph node detection in patients with melanoma – reply. JAMA. 2013;309:232-233.Google Scholar
  36. 36.
    van Akkooi ACJ, Spatz A, Eggermont AMM, Mihm M, Cook MG. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer. 2009;45:2736-2742.Google Scholar
  37. 37.
    Mitteldorf C, Bertsch HP, Zapf A, Neumann C, Kretschmer L. Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients. Mod Pathol. 2009;22:1622-1627.Google Scholar
  38. 38.
    Gutzmer R, Kaspari M, Brodersen JP, et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology. 2002;41:510-518.Google Scholar
  39. 39.
    Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151-157.Google Scholar
  40. 40.
    Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129-142.Google Scholar
  41. 41.
    Hafner J, Hess Schmid M, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150:677-686.Google Scholar
  42. 42.
    Sawyer A, McGoldrick RB, Mackey SP, Allan R, Powell B. Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg. 2009;62:453-456.Google Scholar
  43. 43.
    Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110:1107-1114.Google Scholar
  44. 44.
    Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008;95:1401-1407.Google Scholar
  45. 45.
    Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66:37-45.Google Scholar
  46. 46.
    Bafounta M-L, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol. 2004;5:673-680.Google Scholar
  47. 47.
    Stoffels I, Dissemond J, Poeppel T, et al. Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II. J Eur Acad Dermatol Venereol. 2012;26:79-85.Google Scholar
  48. 48.
    Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244:566-574.Google Scholar
  49. 49.
    Aukema TS, Valdes Olmos RA, Korse CM, et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol. 2010;17:1657-1661.Google Scholar
  50. 50.
    Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer. 1990;66:765-771.Google Scholar
  51. 51.
    Nakajima T, Watanabe S, Sato Y, Kameya T, Hirota T, Shimosato Y. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol. 1982;6:715-727.Google Scholar
  52. 52.
    Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer. 2008;123:2370-2376.Google Scholar
  53. 53.
    Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824-831.Google Scholar
  54. 54.
    Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009;45:1807-1814.Google Scholar
  55. 55.
    Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol. 2008;159:597-605.Google Scholar
  56. 56.
    Dicker TJ, Kavanagh GM, Herd RM, et al; Scottish Melanoma Group. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol. 1999;140:249-254.Google Scholar
  57. 57.
    Murchie P, Hannaford PC, Wyke S, Nicolson MC, Campbell NC. Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health. Fam Pract. 2007;24:283-292.Google Scholar

Copyright information

© Springer Healthcare 2013

Authors and Affiliations

  • Dirk Schadendorf
    • 1
  • Corinna Kochs
    • 2
  • Elisabeth Livingstone
    • 2
  1. 1.Dermatology, Venereology and AllergologyUniversity Hospital EssenEssenGermany
  2. 2.Department for DermatologyUniversity Hospital EssenEssenGermany

Personalised recommendations